Unknown

Dataset Information

0

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.


ABSTRACT: In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

SUBMITTER: Min KJ 

PROVIDER: S-EPMC6393630 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8550930 | biostudies-literature
| S-EPMC4823361 | biostudies-literature
| S-EPMC5512594 | biostudies-other
| S-EPMC5413203 | biostudies-literature
| S-EPMC10948982 | biostudies-literature
| S-EPMC8899870 | biostudies-literature
| S-EPMC3219469 | biostudies-literature
| S-EPMC4876353 | biostudies-literature
| S-EPMC6658599 | biostudies-literature
| S-EPMC5179596 | biostudies-literature